Syncom Formulations

₹13.1 0.1 | 0.5%

WEBSITE BSE:524470 NSE : SYNCOM FORM. 10 May, 16:01

Market Cap ₹1227 Cr.

Stock P/E 46.5

P/B 4.4

Current Price ₹13.1

Book Value ₹ 2.9

Face Value 1

52W High ₹18.7

Dividend Yield 0%

52W Low ₹ 6.1

Edit Ratio

Syncom Formulations Research see more...

Overview Inc. Year: 1988Industry: Pharmaceuticals & Drugs

Syncom Formulations (India) Ltd is a pharmaceutical organisation. The Company manufactures and markets over 300 pharmaceutical formulations merchandise in diverse dosage forms, including tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments, inhalers and herbals. It exports various commodities, including pharmaceutical, which include active pharmaceutical ingredients (APIs) and surgical merchandise; agro and confectionary products, such as rice, wheat flour, chickpeas, soy de oiled cake, biscuits and sweets, and business products, which includes fasteners, metal bars, roofing sheets and jute baggage, and steel scrap. The Company's division, Cratus Life Care, is concerned in looking after domestic marketplace's desires. Its antifungal merchandise consist of Fluconazole Tablets 150 (mg), Itrakonazole Tablets 100 mg, Furazolidone Capsules 100 mg and Itraconazole Capsules 100 mg. Its production facility is positioned at Pithampur, Madhya Pradesh.

Syncom Formulations Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Syncom Formulations Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	53	57	58	51	54	57	61	60	64	65
Other Income	3	2	6	3	3	2	7	2	4	5
Total Income	56	59	64	54	57	59	68	62	68	70
Total Expenditure	47	52	56	48	50	51	55	53	57	58
Operating Profit	8	7	8	6	7	8	13	8	10	12
Interest	0	0	1	1	1	1	1	1	1	1
Depreciation	1	1	1	1	1	1	1	1	1	1
Exceptional Income / Expenses	0	0	-0	0	0	0	0	0	0	-0
Profit Before Tax	7	6	6	5	5	6	10	6	8	9
Provision for Tax	2	2	1	1	2	2	2	2	2	2
Profit After Tax	6	4	5	4	4	4	8	4	7	7
Adjustments	0	0	0	0	0	0	0	-0	0	-0
Profit After Adjustments	6	4	5	4	4	4	8	4	7	7
Adjusted Earnings Per Share	0.1	0	0.1	0	0	0	0.1	0	0.1	0.1

Syncom Formulations Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2022	Mar 2023	TTM
Net Sales	115	151	173	184	185	220	224	250
Other Income	1	1	2	3	3	12	15	18
Total Income	116	152	175	187	188	232	239	268
Total Expenditure	104	135	155	167	168	200	204	223
Operating Profit	12	17	20	19	19	32	34	43
Interest	1	0	0	0	0	2	3	4
Depreciation	3	3	3	3	3	4	5	4
Exceptional Income / Expenses	0	-0	-1	-0	-0	0	0	0
Profit Before Tax	8	14	16	16	16	26	27	33
Provision for Tax	3	5	6	6	5	6	7	8
Profit After Tax	6	9	10	10	11	20	20	26
Adjustments	0	0	0	0	0	0	0	0
Profit After Adjustments	6	9	10	10	11	20	20	26
Adjusted Earnings Per Share	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.3

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	2%	7%	8%	0%
Operating Profit CAGR	6%	21%	15%	0%
PAT CAGR	0%	26%	17%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	114%	30%	67%	13%
ROE Average	8%	10%	10%	9%
ROCE Average	10%	12%	13%	13%

Syncom Formulations Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2022	Mar 2023
Shareholder's Funds	88	95	100	109	117	222	256
Minority's Interest	0	0	0	0	0	0	0
Borrowings	0	0	0	0	0	0	0
Other Non-Current Liabilities	8	7	6	6	8	8	9
Total Current Liabilities	28	42	37	66	59	78	113
Total Liabilities	124	144	143	181	184	308	378
Fixed Assets	50	50	46	46	55	47	43
Other Non-Current Assets	12	15	13	43	42	122	153
Total Current Assets	62	78	84	92	87	140	182
Total Assets	124	144	143	181	184	308	378

Syncom Formulations Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	5	4	5	7	6	3	0
Cash Flow from Operating Activities	6	7	0	24	14	16	11
Cash Flow from Investing Activities	-0	-4	1	-23	-18	-27	-45
Cash Flow from Financing Activities	-6	-1	1	-2	5	8	35
Net Cash Inflow / Outflow	-1	2	1	-1	1	-2	1
Closing Cash & Cash Equivalent	4	5	7	6	7	0	1

Syncom Formulations Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2022	Mar 2023
Earnings Per Share (Rs)	0.07	0.12	0.13	0.13	0.13	0.23	0.21
CEPS(Rs)	0.11	0.16	0.17	0.17	0.17	0.28	0.26
DPS(Rs)	0.06	0.02	0.02	0.02	0.02	0	0
Book NAV/Share(Rs)	1.12	1.22	1.28	1.39	1.5	2.52	2.72
Core EBITDA Margin(%)	9.27	10.73	10.5	8.98	8.96	9.12	8.87
EBIT Margin(%)	7.81	9.49	9.18	8.75	8.77	12.79	13.37
Pre Tax Margin(%)	7.35	9.18	9.01	8.68	8.59	11.92	11.85
PAT Margin (%)	4.92	6.14	5.62	5.58	5.7	9.01	8.95
Cash Profit Margin (%)	7.38	8.12	7.58	7.2	7.39	10.81	10.97
ROA(%)	4.54	6.95	6.82	6.41	5.78	8.04	5.85
ROE(%)	6.45	10.19	9.99	9.91	9.32	11.83	8.48
ROCE(%)	10	15.29	15.55	14.72	13.28	13.72	9.68
Receivable days	91.86	70.22	63.71	75.88	90.83	94.33	116.42
Inventory Days	19.28	19.22	21.92	25.97	25.15	24.52	33.13
Payable days	91.44	87.52	77.52	114.53	140.62	79.52	62.08
PER(x)	29.91	48.62	34.32	16.8	14.6	46.32	27.63
Price/Book(x)	1.93	4.76	3.34	1.6	1.31	4.22	2.17
Dividend Yield(%)	0.79	0.34	0.47	0.9	1.02	0	0
EV/Net Sales(x)	1.46	2.98	1.93	0.95	0.86	4.43	2.81
EV/Core EBITDA(x)	14.2	25.92	16.56	9	8.26	30.42	18.24
Net Sales Growth(%)	0	31.61	14.61	6.06	0.5	18.85	2.09
EBIT Growth(%)	0	60.4	10.64	1.95	-0.16	73.35	6.66
PAT Growth(%)	0	64.72	4.72	6.14	1.72	87.87	1.42
EPS Growth(%)	0	64.55	4.78	6.16	1.66	70.13	-6.97
Debt/Equity(x)	0.02	0.03	0.06	0.05	0.11	0.27	0.32
Current Ratio(x)	2.18	1.88	2.28	1.4	1.47	1.79	1.61
Quick Ratio(x)	1.96	1.64	1.98	1.16	1.3	1.54	1.42
Interest Cover(x)	17.1	30.75	54.58	119.1	48.48	14.58	8.81
Total Debt/Mcap(x)	0.01	0.01	0.02	0.03	0.08	0.06	0.15

Syncom Formulations Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	44.01	46.12	50.57	50.57	50.57	50.57	50.57	50.57	50.57	50.57
FII	0	0	0	0	0	0	0	0	0	0.08
DII	0	0	0	0	0	0	0	0	0	0
Public	55.99	53.88	49.43	49.43	49.43	49.43	49.43	49.43	49.43	49.35
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	36.53	39.78	47.53	47.53	47.53	47.53	47.53	47.53	47.53	47.53
FII	0	0	0	0	0	0	0	0	0	0.07
DII	0	0	0	0	0	0	0	0	0	0
Public	46.47	46.47	46.47	46.46	46.46	46.46	46.46	46.46	46.46	46.39
Others	0	0	0	0	0	0	0	0	0	0
Total	83	86.25	94	94	94	94	94	94	94	94

Pros

Debtor days have improved from 79.52 to 62.08days.
Company is almost debt free.

Cons

Company has a low return on equity of 10% over the last 3 years.
Stock is trading at 4.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Syncom Formulations News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Syncom Formulations

Add Watchlist

Syncom Formulations Research see more...

Overview Inc. Year: 1988Industry: Pharmaceuticals & Drugs

Syncom Formulations Share Price

Alert Data

Quarterly Price

Peer Comparison

Syncom Formulations Quarterly Results

Syncom Formulations Profit & Loss

Growth Rates

Syncom Formulations Balance Sheet

Syncom Formulations Cash Flow

Syncom Formulations Ratios

Syncom Formulations Shareholding Pattern

Syncom Formulations News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!